CDXS - Codexis, Inc.

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
2,6300
+0,0400 (+1,54%)
Alla chiusura: 04:00PM EDT
2,6900 +0,06 (+2,28%)
Dopo ore: 06:26PM EDT
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente2,5900
Aperto2,6000
Denaro2,3900 x 3100
Lettera2,9300 x 1000
Min-Max giorno2,5000 - 2,7100
Intervallo di 52 settimane2,1900 - 13,0300
Volume2.933.741
Media Volume838.753
Capitalizzazione175,599M
Beta (5 anni mensile)1,64
Rapporto PE (ttm)N/D
EPS (ttm)-0,8600
Prossima data utili02 ago 2023 - 07 ago 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A11,14
  • GlobeNewswire

    Codexis to Participate in Jefferies Healthcare Conference

    REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Healthcare Conference, being held June 7-9, 2023, in New York, New York. Management will participate in a fireside chat on Wednesday, June 7, 2023, at 1:00 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will be archived for 9

  • GlobeNewswire

    Codexis Unveils ECO Synthesis™ Platform for Large-Scale RNAi Therapeutics Production at TIDES USA

    --Proprietary technology being developed to address sustainability and scalability challenges of oligonucleotide manufacturing--REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the unveiling of its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology, a proprietary new synthesis platform being developed for manufacturing RNA oligonucleotide therapeutics at scale. The ECO Synthesis™ technology was un

  • GlobeNewswire

    Codexis Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 56,773 shares of Codexis common stock and (ii) restricted stock units (RSUs) for 35,037 shares of Codexis common stock as inducemen

  • GlobeNewswire

    Codexis Reports First Quarter 2023 Financial Results

    CDX-7108 Clinical Development Program Remains on Track Estimated Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Reiterates 2023 Total Revenue Guidance with Adjustments to Product vs. R&D Revenue Mix and Range on Gross Margin REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. “We had a pro

  • GlobeNewswire

    Codexis to Report First Quarter 2023 Financial Results on May 4

    REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be conducting a conference call in conjunction with this financial results release. About Codexis Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to

  • GlobeNewswire

    Codexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USA

    REDWOOD CITY, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a pre-conference workshop highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES USA annual meeting being held May 7-10, 2023, in San Diego, CA. The workshop will be held live and virtually on Sunday, May 7, 2023. Ribonucleic acid (RNA) as a therapeutic modality has gained tremendous traction

  • GlobeNewswire

    Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors

    REDWOOD CITY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined the Board in 2014 and served as the Chair of the Nominating and Corporate Governance Committee. “It has been a privilege to have Pat on the Codexis Board. His expertise in technical operations and manufacturing has been of tremendous value to the company,” s

  • GlobeNewswire

    Codexis to Participate in Cowen 43rd Annual Health Care Conference

    REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, will participate in a panel discussion titled, “SynBio & AI Driven Drug Discovery,” taking place on Mo

  • GlobeNewswire

    Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results

    Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Provides 2023 Revenue Guidance REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a busine

  • GlobeNewswire

    Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency

    Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid AbsorptionREDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, and Nestlé Health Science, a leader in the science of nutrition, today announced interim results from a Phase 1 study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108. CDX-7108 is a lipase variant specifically engineered to overcome the

  • GlobeNewswire

    Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™

    REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19th Annual WORLDSymposium™, taking place from February 22-26, 2023, in Orlando, Florida. Notably, preclinical data in Fabry disease using its engineered transgene is being presented by its partner Takeda Pharmaceutical Company Limited (Takeda). This program is part of Codexis’ Strategic Collabor

  • GlobeNewswire

    Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23

    REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Code

  • GlobeNewswire

    Codexis Announces Appointment of Sri Ryali as Chief Financial Officer

    REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to Codexis. In this role, Mr. Ryali will lead all aspects of the Company’s financial operations and will report directly to Dr. Stephen Dilly, President and Chief Executive Officer of Codexis. “I am ex

  • GlobeNewswire

    Codexis Announces Appointment of H. Stewart Parker to Board of Directors

    REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. “Stewart’s deep expertise in gene therapy and demonstrated track record of executive leadership within the biopharmaceutical industry make her a compelling addition as we seek to continue to strengthen the diversity of our Board with a breadth of professional experience, educational background,

  • GlobeNewswire

    Codexis Provides Update on Prioritized Corporate Strategy

    REDWOOD CITY, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced an update on the Company’s ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and greatest probability of success. As part of this plan, the Company has decided to discontinue investment in certain internal development programs, expand investment in high potential development prog

  • GlobeNewswire

    Codexis to Participate in Piper Sandler 34th Annual Healthcare Conference

    REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held on November 29-December 1, 2022, in New York, New York. The fireside chat is taking place on Thursday, December 1, 2022, at 1:30 p.m. ET. A webcast of the discussion will be available in the Investor

  • GlobeNewswire

    Codexis to Participate in Upcoming Healthcare Conferences

    REDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in three upcoming investor conferences. The Stephens Annual Investment Conference on November 15, 2022, at 2:00 p.m. ET in Nashville, Tennessee – management will participate in an in-person fireside chat. The Stifel 2022 Healthcare Conference on November 16, 2022, at 1:50 p.m. ET in N

  • GlobeNewswire

    Codexis Reports Third Quarter 2022 Financial Results

    Reiterates 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118MREDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. “In the last few months, the leadership team and I have been working to refine Codexis’ strategy by assessing the markets whe

  • GlobeNewswire

    Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel

    REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Margaret (“Meg”) Fitzgerald as Chief Legal Officer and General Counsel, effective immediately. In this role, Ms. Fitzgerald will lead the Company’s legal and compliance functions and provide strategic guidance to the Board of Directors and executive management team. She will report directly to Dr.

  • GlobeNewswire

    Codexis to Report Third Quarter 2022 Financial Results on November 3

    REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2022 on Thursday, November 3, 2022, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access t

  • GlobeNewswire

    Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors

    REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serv

  • GlobeNewswire

    Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer

    REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Kevin Norrett as Chief Operating Officer (COO), effective immediately. In this role, Mr. Norrett is responsible for driving the Company’s corporate growth strategy, business development and operational activities and reports directly to Dr. Stephen Dilly, President and CEO of Codexis. “Kevin brings

  • GlobeNewswire

    Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field

    REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the recent hosting of its in-person Protein Engineering Forum from September 12-13, 2022 in San Francisco, California. This year, the forum brought over 100 top scientists and innovators together to share insights and recent technological advancements across genomics, nucleic acid synthesis and synthetic biology. Ov

  • GlobeNewswire

    Codexis Reports Second Quarter 2022 Financial Results

    Total Revenue up 51% and Product Revenue up 135% YOY 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the second quarter ended June 30, 2022 and provided a business update. “We continue to make solid progress across Codexis’ many exciting growth drivers, and

  • GlobeNewswire

    Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis

    REDWOOD CITY, Calif. and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced the execution of a Commercial License and Enzyme Supply Agreement, enabling Molecular Assemblies to utilize an evolved terminal deoxynucleotidyl transferase (TdT) enzyme in Molecular Assemblies’ Fully Enzymatic Synthesis™